Menu
Recruiting NCT06119789

Precision Cancer Therapy in Rare Cancers

Phase II Interventional Rare Malignant Neoplasm

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Imatinib, Trametinib, Dabrafenib.
Who it may be relevant to
Registry conditions: Rare Malignant Neoplasm. Basic parameters: 16 years — 99 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Norway
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

The MATRIX Clinical Studies of Precision Cancer Therapy for Rare Cancers

Overview

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.

Detailed description

All patients will have the tumour cells diagnosed with a large genepanel, analyzing more than 500 genes on DNA / RNA level. Patients will be treated based on the molecular characteristics of the tumor cells.

Interventions

  • Drug Imatinib
    imatinib treatment based on molecular alterations
  • Drug Trametinib
    According to biomarkers
  • Drug Dabrafenib
    According to biomarkers

Primary outcome measures

  • Radiological response evaluation at 16 weeks of treatment [Time frame: 16 weeks]
Secondary outcome measures (1)
  • Molecular analyses predicting responses [Time frame: 2 years]

Eligibility criteria

Inclusion criteria

  • ECOG 0-2,
  • identified biomarker,
  • reasonable biochemistry

Exclusion criteria

  • ECOG 3-5
  • serious other diseases

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Treatment

Study locations

Norway · 1 center
  • Oslo University Hospital — Oslo

Identifiers

NCT: NCT06119789 · MATRIX-Rare

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗